The LSP Dementia Fund invests in companies that have products or technologies that target neurodegenerative diseases
Dementia is the greatest healthcare challenge of our time. A staggering 50 million patients suffer from dementia worldwide, a number that is predicted to triple to more than 150 million before the year 2050. The burden on our healthcare system is equally large; global costs are currently estimated to amount to over USD 800 billion - or 1.1% of global GDP - and will rise exponentially if no treatment is found. Yet, investments in R&D to find novel treatments are lacking.
In the past two decades, venture capital has proven to play an essential role in advancing biotech companies, but dementia opportunities remain underfunded. Against this backdrop, LSP has launched the LSP Dementia Fund, managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader. The LSP Dementia Fund focuses on all stages of dementia drug and medtech development and as such is the first of its kind in the world. It offers the combination of LSP’s deep investment experience with Philip Scheltens’ impressive scientific acumen and extensive network of dementia experts and research institutions across the globe. The focus is on finding novel treatments to combat the different neurodegenerative diseases that cause dementia, as well as generating a strong financial return for investors. This makes the LSP Dementia Fund a true impact investment.
The investment team has an active and hands-on approach and works closely with portfolio company management teams and co-investors to bring better treatments to patients with dementia. The LSP Dementia Fund will comprise of 10 – 15 investments, primarily located in Europe and the US at various stages of development.
Questions about the LSP Dementia Fund or requests to receive more information are best addressed to Arno de Wilde (neab.qrjvyqr@rdgcnegaref.pbz) or at number +31 (0) 20 664 55 00.
Follow us
The LSP Dementia Fund invests in companies that have products or technologies that target neurodegenerative diseases
Dementia is the greatest healthcare challenge of our time. A staggering 50 million patients suffer from dementia worldwide, a number that is predicted to triple to more than 150 million before the year 2050. The burden on our healthcare system is equally large; global costs are currently estimated to amount to over USD 800 billion - or 1.1% of global GDP - and will rise exponentially if no treatment is found. Yet, investments in R&D to find novel treatments are lacking.
In the past two decades, venture capital has proven to play an essential role in advancing biotech companies, but dementia opportunities remain underfunded. Against this backdrop, LSP has launched the LSP Dementia Fund, managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader. The LSP Dementia Fund focuses on all stages of dementia drug and medtech development and as such is the first of its kind in the world. It offers the combination of LSP’s deep investment experience with Philip Scheltens’ impressive scientific acumen and extensive network of dementia experts and research institutions across the globe. The focus is on finding novel treatments to combat the different neurodegenerative diseases that cause dementia, as well as generating a strong financial return for investors. This makes the LSP Dementia Fund a true impact investment.
The investment team has an active and hands-on approach and works closely with portfolio company management teams and co-investors to bring better treatments to patients with dementia. The LSP Dementia Fund will comprise of 10 – 15 investments, primarily located in Europe and the US at various stages of development.
Questions about the LSP Dementia Fund or requests to receive more information are best addressed to Arno de Wilde (neab.qrjvyqr@rdgcnegaref.pbz) or at number +31 (0) 20 664 55 00.
